Cover Image
市場調查報告書

Humabs BioMed SA:產品平台分析

Humabs BioMed SA - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 305682
出版日期 內容資訊 英文 44 Pages
訂單完成後即時交付
價格
Back to Top
Humabs BioMed SA:產品平台分析 Humabs BioMed SA - Product Pipeline Review - 2016
出版日期: 2016年05月11日 內容資訊: 英文 44 Pages
簡介

Humabs BioMed SA是總公司設立於瑞士的生物科技企業。 利用人體單株抗體平台來藥物發明、開發發炎及感染疾病的治療藥。擁有針對流感,人體巨細胞病毒,B型肝炎,禽流感,黃色葡萄球菌等人體單株抗體的專利。

本報告提供Humabs BioMed SA 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,加上最新的企業新聞和發表,後期階段及中止的計劃相關資訊等。

目錄

Humabs BioMed SA 基本資料

  • Humabs BioMed SA 概要
  • 主要資訊
  • 企業資料

Humabs BioMed SA :R&D概要

  • 主要的治療範圍

Humabs BioMed SA :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Humabs BioMed SA :開發中產品概況

  • 臨床階段的開發中產品
    • 第Ⅱ相的產品/聯合治療模式
    • 第Ⅰ相的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Humabs BioMed SA :藥物簡介

  • Monoclonal Antibody for HCMV Infections
  • FI-6
  • Monoclonal Antibody for Bacterial Infections
  • Monoclonal Antibody for Dengue
  • Monoclonal Antibody for Ebola Virus Infections
  • Monoclonal Antibody for HBV Infections
  • Monoclonal Antibody for Hepatitis C Infection
  • Monoclonal Antibody for Influenza B Infections
  • Monoclonal Antibody for MERS and SARS
  • Monoclonal Antibody for Rabies
  • Monoclonal Antibody for RSV Infections
  • Monoclonal Antibody for Staphylococcus Aureus Infections
  • MPE-8
  • NVB-71.4
  • Monoclonal Antibody for Herpes Simplex Infections
  • Monoclonal Antibody for JCV and BKV Infections
  • Monoclonal Antibody for Solid Tumor
  • Monoclonal Antibody for Undisclosed Indication
  • Monoclonal Antibody to Inhibit GM-CSF for Immunological Disorders

Humabs BioMed SA :開發平台分析

  • 標的別
  • 各分子類型
  • 各作用機制

Humabs BioMed SA :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08047CDB

Summary

Global Markets Direct's, 'Humabs BioMed SA - Product Pipeline Review - 2016', provides an overview of the Humabs BioMed SA's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Humabs BioMed SA, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Humabs BioMed SA
  • The report provides overview of Humabs BioMed SA including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Humabs BioMed SA's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Humabs BioMed SA's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Humabs BioMed SA's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Humabs BioMed SA
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Humabs BioMed SA's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Humabs BioMed SA Snapshot
    • Humabs BioMed SA Overview
    • Key Information
    • Key Facts
  • Humabs BioMed SA - Research and Development Overview
    • Key Therapeutic Areas
  • Humabs BioMed SA - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Humabs BioMed SA - Pipeline Products Glance
    • Humabs BioMed SA - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Humabs BioMed SA - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Humabs BioMed SA - Drug Profiles
    • Monoclonal Antibody for HCMV Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FI-6
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • mAb-100
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • mAb-114
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Dengue
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for HBV Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Influenza B Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Rabies
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Staphylococcus Aureus Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit GM-CSF for Immunological Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MPE-8
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NVB-71.4
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody 1 for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody 2 for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Epstein-Barr Viral Infection
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Viral Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Zika Virus Infection
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Humabs BioMed SA - Pipeline Analysis
  • Humabs BioMed SA - Pipeline Products by Target
  • Humabs BioMed SA - Pipeline Products by Molecule Type
  • Humabs BioMed SA - Pipeline Products by Mechanism of Action
  • Humabs BioMed SA - Dormant Projects
  • Humabs BioMed SA - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Humabs BioMed SA, Key Information
  • Humabs BioMed SA, Key Facts
  • Humabs BioMed SA - Pipeline by Indication, 2016
  • Humabs BioMed SA - Pipeline by Stage of Development, 2016
  • Humabs BioMed SA - Monotherapy Products in Pipeline, 2016
  • Humabs BioMed SA - Partnered Products in Pipeline, 2016
  • Humabs BioMed SA - Partnered Products/ Combination Treatment Modalities, 2016
  • Humabs BioMed SA - Out-Licensed Products in Pipeline, 2016
  • Humabs BioMed SA - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Humabs BioMed SA - Phase II, 2016
  • Humabs BioMed SA - Phase I, 2016
  • Humabs BioMed SA - Preclinical, 2016
  • Humabs BioMed SA - Discovery, 2016
  • Humabs BioMed SA - Pipeline by Target, 2016
  • Humabs BioMed SA - Pipeline by Molecule Type, 2016
  • Humabs BioMed SA - Pipeline Products by Mechanism of Action, 2016
  • Humabs BioMed SA - Dormant Developmental Projects,2016

List of Figures

  • Humabs BioMed SA - Pipeline by Top 10 Indication, 2016
  • Humabs BioMed SA - Pipeline by Stage of Development, 2016
  • Humabs BioMed SA - Monotherapy Products in Pipeline, 2016
  • Humabs BioMed SA - Pipeline by Target, 2016
  • Humabs BioMed SA - Pipeline by Molecule Type, 2016
  • Humabs BioMed SA - Pipeline Products by Mechanism of Action, 2016
Back to Top